These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 17272793)
21. The role of vildagliptin in the management of type 2 diabetes mellitus. Kleppinger EL; Helms K Ann Pharmacother; 2007 May; 41(5):824-32. PubMed ID: 17456545 [TBL] [Abstract][Full Text] [Related]
22. What are incretins, and how will they influence the management of type 2 diabetes? Blonde L; Rosenstock J; Triplitt C J Manag Care Pharm; 2006 Sep; 12(7 Suppl A):S2-12; quiz S14-6. PubMed ID: 16981805 [TBL] [Abstract][Full Text] [Related]
23. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes. Jellinger PS Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084 [TBL] [Abstract][Full Text] [Related]
24. Synthetic and phytocompounds based dipeptidyl peptidase-IV (DPP-IV) inhibitors for therapeutics of diabetes. Singh AK; Jatwa R; Purohit A; Ram H J Asian Nat Prod Res; 2017 Oct; 19(10):1036-1045. PubMed ID: 28351157 [TBL] [Abstract][Full Text] [Related]
25. Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Vella A; Bock G; Giesler PD; Burton DB; Serra DB; Saylan ML; Dunning BE; Foley JE; Rizza RA; Camilleri M Diabetes; 2007 May; 56(5):1475-80. PubMed ID: 17303799 [TBL] [Abstract][Full Text] [Related]
26. Looking to the future: focus on DPP-4 inhibitors for the treatment of type 2 diabetes and emerging therapies. Neumiller JJ; Odegard PS; White JR; Setter SM; Campbell RK Diabetes Educ; 2008; 34(2):183-200. PubMed ID: 18375772 [TBL] [Abstract][Full Text] [Related]
27. Incretin-based therapies in type 2 diabetes: a review of clinical results. Bosi E; Lucotti P; Setola E; Monti L; Piatti PM Diabetes Res Clin Pract; 2008 Dec; 82 Suppl 2():S102-7. PubMed ID: 19022515 [TBL] [Abstract][Full Text] [Related]
28. Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1. Duffy NA; Green BD; Irwin N; Gault VA; McKillop AM; O'Harte FP; Flatt PR Eur J Pharmacol; 2007 Jul; 568(1-3):278-86. PubMed ID: 17573070 [TBL] [Abstract][Full Text] [Related]
29. The incretin system and its role in type 2 diabetes mellitus. Holst JJ; Vilsbøll T; Deacon CF Mol Cell Endocrinol; 2009 Jan; 297(1-2):127-36. PubMed ID: 18786605 [TBL] [Abstract][Full Text] [Related]
30. Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus. Freeman JS Cleve Clin J Med; 2009 Dec; 76 Suppl 5():S12-9. PubMed ID: 19952298 [TBL] [Abstract][Full Text] [Related]
31. Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo. Kim SH; Jung E; Yoon MK; Kwon OH; Hwang DM; Kim DW; Kim J; Lee SM; Yim HJ Eur J Pharmacol; 2016 Oct; 788():54-64. PubMed ID: 27298192 [TBL] [Abstract][Full Text] [Related]
33. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Thornberry NA; Gallwitz B Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):479-86. PubMed ID: 19748065 [TBL] [Abstract][Full Text] [Related]
34. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Ahrén B; Schweizer A; Dejager S; Villhauer EB; Dunning BE; Foley JE Diabetes Obes Metab; 2011 Sep; 13(9):775-83. PubMed ID: 21507182 [TBL] [Abstract][Full Text] [Related]
35. Dipeptidyl peptidase IV and its inhibitors: therapeutics for type 2 diabetes and what else? Juillerat-Jeanneret L J Med Chem; 2014 Mar; 57(6):2197-212. PubMed ID: 24099035 [TBL] [Abstract][Full Text] [Related]
36. Educating patients with type 2 diabetes on a new class of drug, dipeptidyl peptidase 4 inhibitors. Siminerio L Diabetes Educ; 2007; 33 Suppl 5():111S-3S. PubMed ID: 17548898 [No Abstract] [Full Text] [Related]